Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) EBITDA (2016 - 2025)

Historic EBITDA for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $197000.0.

  • Harvard Bioscience's EBITDA rose 11051.23% to $197000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.3 million, marking a year-over-year decrease of 74644.78%. This contributed to the annual value of -$6.2 million for FY2024, which is 42793.03% down from last year.
  • As of Q3 2025, Harvard Bioscience's EBITDA stood at $197000.0, which was up 11051.23% from -$819000.0 recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's EBITDA peaked at $4.0 million during Q2 2022, and registered a low of -$49.7 million during Q1 2025.
  • Over the past 5 years, Harvard Bioscience's median EBITDA value was -$239000.0 (recorded in 2021), while the average stood at -$3.1 million.
  • The largest annual percentage gain for Harvard Bioscience's EBITDA in the last 5 years was 679310.34% (2022), contrasted with its biggest fall of 270836.82% (2022).
  • Harvard Bioscience's EBITDA (Quarter) stood at $1.7 million in 2021, then tumbled by 126.9% to -$457000.0 in 2022, then skyrocketed by 161.71% to $282000.0 in 2023, then tumbled by 96.1% to $11000.0 in 2024, then surged by 1690.91% to $197000.0 in 2025.
  • Its EBITDA stands at $197000.0 for Q3 2025, versus -$819000.0 for Q2 2025 and -$49.7 million for Q1 2025.